GRIN3B

Glutamate receptor ionotropic, NMDA 3B (GluN3 · O60391 · GRIN3B on Sugi Atlas →

93,239 patent compounds predicted against GRIN3B, 52,386 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Ditolylguanidine (SCHEMBL80339)	1.00	14/20
SCHEMBL123451	0.55	14/20
SCHEMBL121942	1.00	11/20
Guanabenz (SCHEMBL15390)	0.65	11/20
Memantine (SCHEMBL2688)	1.00	9/20
Memantine (SCHEMBL2689)	1.00	9/20
Memantine (SCHEMBL3053)	0.95	9/20
Levorphanol (SCHEMBL24335)	1.00	8/20
Racemorphan (SCHEMBL46201)	1.00	8/20
Dextrorphan (SCHEMBL115577)	1.00	8/20
SCHEMBL103596	0.44	8/20
Dextromethorphan (SCHEMBL29949)	1.00	7/20
Levomethorphan (SCHEMBL29950)	1.00	7/20
SCHEMBL78658	1.00	7/20
Radiprodil (SCHEMBL99256)	1.00	7/20
Racemethorphan (SCHEMBL118520)	1.00	7/20
Radiprodil (SCHEMBL134435)	0.98	7/20
Radiprodil (SCHEMBL135546)	0.98	7/20
Dextromethorphan (SCHEMBL121924)	0.98	7/20
Dextrorphan (SCHEMBL122564)	0.98	7/20

Clinical trials — most relevant to GRIN3B by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
PCA Ketamine-Morphine VS PCA Morphine as Post-Operative Analgesia in Colorectal Surgery.	PHASE4	COMPLETED
Treatment of Cognitive and Negative Symptoms in Schizophrenia With N-acetylcysteine	PHASE4	COMPLETED
TAP-GRIN: Interventional Study on Patients With GRIN-related Neurodevelopmental Disorders	PHASE3	RECRUITING
A Randomized, Double-Blind Controlled Comparison of NRX-101 vs. Placebo for Adults Being Treated With Robotic Transcranial Magnetic Stimulation for Treatment Resistant Depression: The SPARC-TMS Trial	PHASE2/PHASE3	NOT_YET_RECRUITING
A Randomized, Clinical Trial of Vitamin E and Memantine in Alzheimer's Disease	PHASE3	COMPLETED
Memantine for Refractory OCD Patients	PHASE3	UNKNOWN
Prehospital Early Administration of Ketamine for Status Epilepticus in Epileptic Kids (PEAK-SEEK)	PHASE2/PHASE3	RECRUITING
Effect of Sarcosine on Symptomatology, Quality of Life, Oxidative Stress and Glutamatergic Parameters in Schizophrenia	PHASE2	COMPLETED
Antidepressant Effects of the Glycine Receptor Antagonist AV-101 (4-chlorokynurenine) in Major Depressive Disorder	PHASE2	COMPLETED
High Dose D-Serine as Adjuvant Treatment for Recent Onset Schizophrenia	PHASE2	UNKNOWN
Neurobiology of a Mutation in Glycine Metabolism in Psychotic Disorders	PHASE2	COMPLETED
Effects of Direct Transcranial Current Stimulation on Central Neural Pain Processing in Fibromyalgia	PHASE1/PHASE2	COMPLETED
Dextromethorphan, Amantadine and Glucose Homeostasis in Diabetes Subjects	PHASE2	COMPLETED
Mechanism of Action Underlying Ketamine's Antidepressant Effects: The AMPA Throughput Theory in Patients With Treatment-Resistant Major Depression	PHASE1	RECRUITING
Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response, Pilot Trial	PHASE1	COMPLETED
Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response	PHASE1	RECRUITING
Antidepressant Effects of NR2B in Major Depression	PHASE1	COMPLETED
D-aspartate and Therapeutic Exercise	EARLY_PHASE1	UNKNOWN
Targeting a Genetic Mutation in Glycine Metabolism With D-cycloserine	EARLY_PHASE1	COMPLETED
Tolerability and Efficacy of L-Serine in Patients With GRIN-related Encephalopathy	nan	UNKNOWN
The Impact of Pharmacological and Electric Modulation of NMDA Pathway on the Cognitive Flexibility and Volitional Movement Preparation in Patients With Parkinson's Disease	nan	COMPLETED
Acamprosate: Genes Associated With Response	nan	COMPLETED
An Assessment of Cognitive Function in Irritable Bowel Syndrome	nan	UNKNOWN
Integrins and Protocadherins in Glutamatergic Circuits: Identification of Common Signaling Pathways and Molecular Targets in Anxiety and Major Depressive Disorders (GAPsy)	nan	UNKNOWN
The Neuroprotective Effect of Dexmedetomidine Preserving Brain Functional Connectivity in Elderly Patients	nan	COMPLETED
Mechanisms of Human Plasticity in the Human System	nan	COMPLETED
PET Imaging of Brain mGluR1 Receptors Using [18F]FIMX	nan	COMPLETED
Exploiting Leading Edge 7T MRI Brain Imaging to Decipher Olumiant's Mode of Analgesic Action in Rheumatoid Arthritis	nan	COMPLETED
Effect of Dexmedetomidine Combined With Low-dose Nalmefene on Preventing Remifentanil-induced Postoperative Hyperalgesia	nan	COMPLETED
Pulsed Electro Magnetic Fields (PEMF) in Depression	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a GRIN3B binder may also engage these)

Protein	Name	Similarity
Q91ZU9	—	0.995	Q91ZU9 →
Q8VHN2	—	0.989	Q8VHN2 →
Q62645	—	0.982	Q62645 →
Q03391	—	0.981	Q03391 →
GRIN2D	Glutamate receptor ionotropic, NMDA 2D	0.981	landscape →
Q6PJG9	—	0.956	Q6PJG9 →
Q80XU8	—	0.955	Q80XU8 →
Q86UW8	—	0.951	Q86UW8 →
D4ABX8	—	0.951	D4ABX8 →
Q00961	—	0.948	Q00961 →
Q8NE01	—	0.948	Q8NE01 →
Q80WM4	—	0.946	Q80WM4 →
Q6ZMM2	—	0.946	Q6ZMM2 →
GRIN2C	Glutamate receptor ionotropic, NMDA 2C	0.945	landscape →
Q9UJ96	—	0.945	Q9UJ96 →
Q9HB15	—	0.945	Q9HB15 →
Q9P244	—	0.944	Q9P244 →
GRM6	Metabotropic glutamate receptor 6	0.944	landscape →
Q96QI5	—	0.944	Q96QI5 →
Q9Y644	—	0.944	Q9Y644 →
Q32NY4	—	0.943	Q32NY4 →
Q924T4	—	0.942	Q924T4 →
Q0VCH4	—	0.942	Q0VCH4 →
Q01098	—	0.942	Q01098 →
Q1RMS4	—	0.941	Q1RMS4 →
Q96A11	—	0.941	Q96A11 →
P23726	—	0.941	P23726 →
O54951	—	0.941	O54951 →
P61315	—	0.940	P61315 →
O70141	—	0.940	O70141 →